Results 11 to 18 of about 24 (18)

Monoclonal antibody therapies for aquaporin-4-immunoglobulin G-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease. [PDF]

Saudi J Ophthalmol
Tisavipat N, Juan HY, Chen JJ.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Efficacy and safety of divozilimab during 24-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-2

S.S. Korsakov Journal of Neurology and Psychiatry, 2023
Objective. To find the optimal therapeutic dose of the anti-B cell mAb divozilimab (DIV) based on the efficacy and safety data of intravenous administration at a dose of 125 mg or 500 mg in patients with relapsing remitting multiple sclerosis (RRMS) compared to placebo (PBO) and teriflunomide (TRF).
A.N. Boyko, V.M. Alifirova, I.G. Lukashevich, Z.A. Goncharova, I.V. Greshnova, L.G. Zaslavsky, S.V. Kotov, N.A. Malkova, G.N. Mishin, E.V. Parshina, I.Ye. Poverennova, L.N. Prakhova, S.A. Sivertseva, I.V. Smagina, N.A. Totolyan, Yu.V. Trinitatsky, T.N. Trushnikova, F.A. Khabirov, S.G. Shchur, A.V. Artemyeva, D.D. Bolsun, A.V. Zinkina-Orikhan, Yu.N. Linkova   +22 more
openaire   +2 more sources

Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS

S.S. Korsakov Journal of Neurology and Psychiatry, 2023
Objective. To evaluate the efficacy and safety of the anti-CD20 monoclonal antibody divozilimab (DIV) used as an intravenous infusion at a dose of 500 mg for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS) in comparison with the teriflunomide (TRF). The study of the efficacy and safety of the use of the drug DIV was carried
A.N. Boyko, V.M. Alifirova, I.G. Lukashevich, Z.A. Goncharova, I.V. Greshnova, L.G. Zaslavsky, S.V. Kotov, N.A. Malkova, G.N. Mishin, E.V. Parshina, I.Ye. Poverennova, L.N. Prakhova, S.A. Sivertseva, I.V. Smagina, N.A. Totolyan, Yu.V. Trinitatsky, T.N. Trushnikova, F.A. Khabirov, J.Yu. Chefranova, S.G. Shchur, V.A. Dudin, D.V. Pokhabov, D.D. Bolsun, A.V. Eremeeva, Yu.N. Linkova, A.V. Zinkina-Orikhan   +25 more
openaire   +2 more sources

The first experience with the use of divozilimab in the treatment of multiple sclerosis patients in daily clinical practice

S.S. Korsakov Journal of Neurology and Psychiatry
Objective. The aim of this study is to assess the efficacy and safety of divozilimab in patients who have received post-marketing treatment and participants of clinical trials BCD-132-2 and BCD-132-4 were conducted at the IHB RAS. Additionally, we will present a case report of divozilimab therapy in a patient with highly active multiple sclerosis (MS).
V.M. Lebedev, E.D. Kuzminykh
openaire   +2 more sources

Comparing the efficacy of divozilimab and second-line treatments for relapsing-remitting multiple sclerosis in the Russian Federation: a systematic review and network meta-analysis

S.S. Korsakov Journal of Neurology and Psychiatry
Objective. To compare efficacy of the new drug divozilimab with other second-line treatment options for relapsing remitting multiple sclerosis (RRMS) that have been already included or submitted application to be included into the «14 high-cost nosologies» program in the Russian Federation. Material and methods.
M.N. Zakharova, T.O. Simaniv, K.V. Sapozhnikov, D.G. Tolkacheva, V.D. Sokolova, N.A. Sableva, O.N. Mironenko, A.A. Lazarev, T.V. Khimich   +8 more
openaire   +2 more sources

Results of 4 years of therapy with divozilimab in patients with relapsing multiple sclerosis

S.S. Korsakov Journal of Neurology and Psychiatry
Objective. To assess the efficacy and safety of long-term treatment with divozilimab in patients with relapsing multiple sclerosis (MS). Material and methods. Study No. BCD-132-EXT enrolled patients with relapsing MS who had previously received divozilimab at a dose of 500 mg in a phase II and III studies.
A.N. Boyko, V.M. Alifirova, Z.A. Goncharova, I.V. Greshnova, L.G. Zaslavsky, S.V. Kotov, G.N. Mishin, E.V. Parshina, I.Ye. Poverennova, S.A. Sivertseva, N.A. Totolyan, Yu.V. Trinitatsky, T.N. Trushnikova, I.A. Sokolova, I.A. Shukin, V.A. Dudin, D.V. Pokhabov, M.V. Krasnova, A.A. Porozova, A.V. Eremeeva, Yu.N. Linkova, A.V. Zinkina-Orikhan   +21 more
openaire   +1 more source

Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS

S.S. Korsakov Journal of Neurology and Psychiatry
Objective. To evaluate the efficacy and safety of the anti-CD20 monoclonal antibody divozilimab (DIV) used as an intravenous infusion at a dose of 500 mg every 24 weeks during 100 weeks for the treatment of patients with multiple sclerosis (MS), including relapsing-remitting multiple sclerosis (RRMS) and secondary progressive MS (SPMS) with relapses ...
A.N. Boyko, V.M. Alifirova, I.G. Lukashevich, Z.A. Goncharova, I.V. Greshnova, L.G. Zaslavsky, S.V. Kotov, N.A. Malkova, G.N. Mishin, E.V. Parshina, I.Ye. Poverennova, L.N. Prakhova, S.A. Sivertseva, I.V. Smagina, N.A. Totolyan, Yu.V. Trinitatsky, T.N. Trushnikova, F.A. Khabirov, J.Yu. Chefranova, S.G. Shchur, V.A. Dudin, D.V. Pokhabov, A.V. Artemeva, A.V. Eremeeva, Yu.N. Linkova, A.V. Zinkina-Orikhan   +25 more
openaire   +2 more sources

New Anti-Cd20 Divozilimab in Relapsing Multiple Sclerosis: Phase III MIRANTIBUS Trial Results

Multiple Sclerosis and Related Disorders, 2023
Alexey Boyko, Yulia Linkova, Arina Zinkina-Orikhan, Anastasia Porozova   +3 more
openaire   +1 more source